West Pharmaceutical Services (WST)
(Delayed Data from NYSE)
$303.33 USD
-6.38 (-2.06%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $303.28 -0.05 (-0.02%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Company Summary
West Pharmaceutical Services Inc. is a leading global manufacturer with respect to design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. The Exton, PA-based company designs and produces these medical products in the Americas, Europe, the Middle East, Africa and the Asia Pacific. Its primary objective is to deliver quality products that cater to the exact product specifications and quality standards that customers expect and need. West Pharmaceutical operates through two segments – Proprietary Products and Contract-Manufactured Products.
Proprietary Products segment provides ...
Company Summary
West Pharmaceutical Services Inc. is a leading global manufacturer with respect to design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. The Exton, PA-based company designs and produces these medical products in the Americas, Europe, the Middle East, Africa and the Asia Pacific. Its primary objective is to deliver quality products that cater to the exact product specifications and quality standards that customers expect and need. West Pharmaceutical operates through two segments – Proprietary Products and Contract-Manufactured Products.
Proprietary Products segment provides packaging, containment and drug delivery products, together with analytical lab services and other integrated services and solutions mainly to biologic, generic and pharmaceutical drug customers. This segment’s product portfolio also comprises drug containment solutions, including Crystal Zenith – a cyclic olefin polymer, in the form of vials, syringes and cartridges. Additionally, the company provides a range of self-injection devices, which have been developed to meet the need to offer at-home delivery of injectable therapies. The segment has manufacturing facilities in North and South America, Europe and Asia Pacific, with affiliated companies in Mexico and Japan.
Contract-Manufactured Products segment acts as a fully-integrated business, which remains committed toward the design, manufacture and automated assembly of complex devices, mainly for pharmaceutical, diagnostic, and medical device customers. The business manufactures consumer-owned components and devices utilized in surgical, diagnostic, injectable and other drug delivery systems along with consumer products. The segment has manufacturing facilities in North America and Europe.
2023 at a GlanceFull-year 2023 net sales of 2.95 billion increased 2.2% on a year-over-year basis.
Proprietary Products segment net sales (81.4% of net sales) declined 0.4% to $2.4 billion, while Contract-Manufactured Products (18.6%) net sales climbed 15% to $552.5 million.
General Information
West Pharmaceutical Services, Inc
530 HERMAN O. WEST DRIVE
EXTON, PA 19341
Phone: 610-594-2900
Fax: 800-345-9800
Web: http://www.westpharma.com
Email: quintin.lai@westpharma.com
Industry | Medical - Dental Supplies |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 10/24/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 1.51 |
Current Year EPS Consensus Estimate | 6.42 |
Estimated Long-Term EPS Growth Rate | 4.40 |
Exp Earnings Date | 10/24/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 309.71 |
52 Week High | 413.70 |
52 Week Low | 265.00 |
Beta | 1.01 |
20 Day Moving Average | 393,239.84 |
Target Price Consensus | 352.50 |
4 Week | 2.34 |
12 Week | -4.00 |
YTD | -12.04 |
4 Week | 0.43 |
12 Week | -7.75 |
YTD | -26.82 |
Shares Outstanding (millions) | 72.54 |
Market Capitalization (millions) | 22,466.86 |
Short Ratio | NA |
Last Split Date | 9/27/2013 |
Dividend Yield | 0.26% |
Annual Dividend | $0.80 |
Payout Ratio | 0.11 |
Change in Payout Ratio | 0.00 |
Last Dividend Payout / Amount | 7/31/2024 / $0.20 |
Fundamental Ratios
P/E (F1) | 48.21 |
Trailing 12 Months | 43.81 |
PEG Ratio | 11.04 |
vs. Previous Year | -27.96% |
vs. Previous Quarter | -2.56% |
vs. Previous Year | -6.86% |
vs. Previous Quarter | 0.96% |
Price/Book | 8.72 |
Price/Cash Flow | 30.43 |
Price / Sales | 7.81 |
6/30/24 | 19.17 |
3/31/24 | 20.57 |
12/31/23 | 21.60 |
6/30/24 | 14.38 |
3/31/24 | 15.47 |
12/31/23 | 16.26 |
6/30/24 | 2.34 |
3/31/24 | 2.61 |
12/31/23 | 2.88 |
6/30/24 | 1.68 |
3/31/24 | 1.95 |
12/31/23 | 2.24 |
6/30/24 | 18.34 |
3/31/24 | 19.62 |
12/31/23 | 20.64 |
6/30/24 | 18.25 |
3/31/24 | 19.42 |
12/31/23 | 20.12 |
6/30/24 | 21.25 |
3/31/24 | 22.79 |
12/31/23 | 23.66 |
6/30/24 | 35.52 |
3/31/24 | 36.80 |
12/31/23 | 39.31 |
6/30/24 | 4.31 |
3/31/24 | 4.22 |
12/31/23 | 4.13 |
6/30/24 | 0.03 |
3/31/24 | 0.03 |
12/31/23 | 0.03 |
6/30/24 | 2.75 |
3/31/24 | 2.64 |
12/31/23 | 2.46 |